A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
Status:
RECRUITING
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
This Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma.
The main goals of this study are to investigate how effective KT-621 is at treating uncontrolled moderate to severe eosinophilic asthma, the safety and tolerability of KT-621, and how KT-621 behaves in the body.